S855-119

Reported

To require executive branch employees to report certain royalties, and for other purposes.

119th Congress Introduced Mar 5, 2025

Summary

What This Bill Does

The Royalty Transparency Act makes federal invention royalties and ethics waivers more visible. It adds members of major public-health and science advisory committees to financial-disclosure coverage, requires GAO to publish annual lists of covered committees, requires reporting of the source and value of royalties tied to inventions developed in government employment, requires ethics waivers and exemptions to be reported to Congress with justification, requires agencies to furnish mostly unredacted disclosure reports to Members of Congress, requires annual public reports listing covered individuals and royalty sources and values, and directs procurement officials to update organizational-conflict-of-interest rules.

Who Benefits and How

Congressional oversight committees benefit from royalty disclosures, waiver justifications, and access to executive branch financial disclosure reports. The public benefits from agency websites listing covered officials and the original source and value of reported royalties. Government ethics watchdogs benefit from clearer information about royalties received by officials, spouses, and dependent children. Federal procurement officers benefit from updated organizational-conflict-of-interest rules for advisory or contractor roles.

Who Bears the Burden and How

Executive branch employees and special government employees who receive federal invention royalties must disclose original source and value information. Public-health advisory committee members face expanded financial-disclosure coverage if their recommendations were implemented. Agency ethics offices must publish reports, respond to congressional requests, and track confidential disclosure filers. GAO, OGE, OMB, and the Federal Acquisition Regulatory Council must produce lists, consult on reporting, and update regulations.

Key Provisions

  • Expands financial-disclosure coverage to members of specified public-health and science advisory committees.
  • Requires disclosure of original source and amount or value of royalties tied to inventions developed during federal employment.
  • Requires ethics waivers and exemptions to be reported to Congress with detailed justifications.
  • Directs agencies to publish annual royalty reports and furnish mostly unredacted reports to Members of Congress.
  • Requires procurement regulators to update organizational-conflict-of-interest rules.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

Expands royalty and conflict-of-interest transparency for executive branch employees and public-health advisory committee members, requiring disclosure of federal invention royalties, congressional access to reports, annual agency publication, GAO committee lists, and acquisition conflict rules.

Key Policy Areas

Government Ethics, Public Health, Federal Procurement

Primary Purpose

Expands royalty and conflict-of-interest transparency for executive branch employees and public-health advisory committee members, requiring disclosure of federal invention royalties, congressional access to reports, annual agency publication, GAO committee lists, and acquisition conflict rules.

Policy Domains

Government Ethics Public Health Federal Procurement

Bill provisions

Identified Gains
  • Congressional oversight committees
  • Public watchdog groups
  • Government ethics offices
  • Federal procurement officers
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: is
Public watchdog groups: ,
Government ethics offices: ,
Federal procurement officers: ,
Congressional oversight committees: ,
Identified Costs
  • Executive branch employees receiving royalties
  • Public-health advisory committee members
  • Agency ethics offices
  • GAO
  • Federal Acquisition Regulatory Council
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: is
GAO: ,
Agency ethics offices: ,
Federal Acquisition Regulatory Council: ,
Public-health advisory committee members: ,
Executive branch employees receiving royalties: ,

Legislative Progress

Reported
Introduced Committee Passed
Sep 17, 2025

Reported by Mr. Paul, with amendments

Mar 5, 2025

Mr. Paul (for himself and Mr. Scott of Florida) introduced …

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Government
18 mentions across 3 clauses
+9 positive -9 negative

Agency ethics offices, Congressional oversight committees, Federal Acquisition Regulatory Council

Positive-direction: Congressional oversight committees, Federal procurement officers, Government ethics offices

Negative-direction: Agency ethics offices, Federal Acquisition Regulatory Council, GAO

Nonprofits
3 mentions across 3 clauses
+3 positive

Public watchdog groups

Government Employees
3 mentions across 3 clauses
-3 negative

Executive branch employees receiving royalties

General Public
3 mentions across 3 clauses
-3 negative

Public-health advisory committee members

1/4
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Government Ethics Public Health Federal Procurement
Actor Mappings
"gao"
→ Government Accountability Office
"oge"
→ Office of Government Ethics

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology